Ongoing grants

Damon Runyon Cancer Foundation
Lujambio (PI) 01/01/18-12/31/21
Overcoming resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma.

RO1 NIH, R37 MERIT Award
Lujambio (PI) 07/01/18-06/30/23
Tumor intrinsic signaling pathways promote immune escape in hepatocellular carcinoma.

Lujambio (Co-PI) 07/01/19-06/30/20
Predicting response to immunotherapy in hepatocellular carcinoma by dissecting the gut microbiome: a pilot study.

R01 CA251155-01
Lujambio (MPI) 07/01/20-06/30/25
Targeting tumor metabolism and immune environment via beta-catenin: Towards precision medicine in HCC.

Pfizer Collaboration Grant
Lujambio (PI) 09/01/20-08/31/22
Target discovery and cross-lineage pharmacology studies in tailored genetic models.

Genentech Collaboration Grant
Lujambio (PI) 01/01/19-12/31/20
Efficacy and mechanism of action study on a-PD-L1 and a-VEGF combination in HCC mouse models.


Past grants

AASLD. Pinnacle Research Award in Liver Disease
Lujambio (PI) 07/01/15-09/30/16
RNAi screen for combination therapy discovery in liver cancer.

TCI Developmental Fund
Lujambio (Co-PI) 01/01/17-12/31/17
Mechanisms of Action and Synergies of a Novel Small Molecule in Liver Cancer.

Pfizer Collaboration Grant
Lujambio (PI) 12/01/16-11/30/18
An immunocompetent target discovery pipeline for liver cancer.

DoD Career Development Award
Lujambio (PI) 09/30/16-09/29/19
Functional genomics screen for combination therapy discovery in liver cancer.

DoD Translational Team Science Award
Lujambio (Co-PI) 09/01/16-08/31/20
Mechanisms of acquired resistance to sorafenib in hepatocellular carcinoma.

TCI Developmental Fund
Lujambio (Co-PI) 01/01/18-12/31/19
Combination immunotherapies for CTNNB1-mutant hepatocellular carcinomas.

Stony Brook-Mount Sinai Pilot Grant
Lujambio (Co-PI) 07/01/18-12/31/19
Mutant p53: a novel therapeutic target in liver and pancreatic cancer.